Kohjin Bio (177A) · RiskDropped
Decline in commissioned projects due to intensifying competition among cell processing providers
First written in FY2026-H1. 1 of 2 entries say "Dropped", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of Intensifying Competition and Shortfall in Demand in the Regenerative Medicine-Related MarketA theme 6 companies write about · 7 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026DroppedAnnual report
「The number of inbound patients stagnated as the number of visitors to Japan from China declined against a backdrop of worsening Japan-China relations and other factors.」
During the fiscal year, intensifying competition among cell-processing companies was not cited as a factor behind the decline in contracted cell-processing projects; instead, the decline in visitors to Japan from China and Japan-China relations were the main explanations. - FY2026-H1First statedAnnual report
「In contracted cell processing, inbound demand has remained high, but the number of cell-processing contracts from contracted medical institutions has been trending down as competition among cell-processing companies has intensified.」
In addition to the high level of inbound demand, the company newly states that the number of contracts from contracted medical institutions has been trending down against a backdrop of intensifying competition among cell-processing companies.